110 related articles for article (PubMed ID: 21166923)
21. Antagonist of the neurokinin-1 receptor curbs neuroinflammation in ex vivo and in vitro models of Lyme neuroborreliosis.
Martinez AN; Ramesh G; Jacobs MB; Philipp MT
J Neuroinflammation; 2015 Dec; 12():243. PubMed ID: 26714480
[TBL] [Abstract][Full Text] [Related]
22. Lipopolysaccharide modulates neutrophil recruitment and macrophage polarization on lymphatic vessels and impairs lymphatic function in rat mesentery.
Chakraborty S; Zawieja SD; Wang W; Lee Y; Wang YJ; von der Weid PY; Zawieja DC; Muthuchamy M
Am J Physiol Heart Circ Physiol; 2015 Dec; 309(12):H2042-57. PubMed ID: 26453331
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA signature of inflamed lymphatic endothelium and role of miR-9 in lymphangiogenesis and inflammation.
Chakraborty S; Zawieja DC; Davis MJ; Muthuchamy M
Am J Physiol Cell Physiol; 2015 Nov; 309(10):C680-92. PubMed ID: 26354749
[TBL] [Abstract][Full Text] [Related]
24. IL-1β reduces tonic contraction of mesenteric lymphatic muscle cells, with the involvement of cycloxygenase-2 and prostaglandin E2.
Al-Kofahi M; Becker F; Gavins FN; Woolard MD; Tsunoda I; Wang Y; Ostanin D; Zawieja DC; Muthuchamy M; von der Weid PY; Alexander JS
Br J Pharmacol; 2015 Aug; 172(16):4038-51. PubMed ID: 25989136
[TBL] [Abstract][Full Text] [Related]
25. Emerging trends in the pathophysiology of lymphatic contractile function.
Chakraborty S; Davis MJ; Muthuchamy M
Semin Cell Dev Biol; 2015 Feb; 38():55-66. PubMed ID: 25617600
[TBL] [Abstract][Full Text] [Related]
26. Functional adaptation of bovine mesenteric lymphatic vessels to mesenteric venous hypertension.
Quick CM; Criscione JC; Kotiya A; Dongaonkar RM; Hardy J; Wilson E; Gashev AA; Laine GA; Stewart RH
Am J Physiol Regul Integr Comp Physiol; 2014 Jun; 306(12):R901-7. PubMed ID: 24671245
[TBL] [Abstract][Full Text] [Related]
27. Cytokines are systemic effectors of lymphatic function in acute inflammation.
Aldrich MB; Sevick-Muraca EM
Cytokine; 2013 Oct; 64(1):362-9. PubMed ID: 23764549
[TBL] [Abstract][Full Text] [Related]
28. Lymphatic filariasis: perspectives on lymphatic remodeling and contractile dysfunction in filarial disease pathogenesis.
Chakraborty S; Gurusamy M; Zawieja DC; Muthuchamy M
Microcirculation; 2013 Jul; 20(5):349-64. PubMed ID: 23237232
[TBL] [Abstract][Full Text] [Related]
29. Neurokinin receptors in drug and alcohol addiction.
Schank JR
Brain Res; 2020 May; 1734():146729. PubMed ID: 32067964
[TBL] [Abstract][Full Text] [Related]
30. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs.
Ebrahimi S; Javid H; Alaei A; Hashemy SI
Clin Genet; 2020 Oct; 98(4):322-330. PubMed ID: 32266968
[TBL] [Abstract][Full Text] [Related]
31. Substance P activates both contractile and inflammatory pathways in lymphatics through the neurokinin receptors NK1R and NK3R.
Chakraborty S; Nepiyushchikh Z; Davis MJ; Zawieja DC; Muthuchamy M
Microcirculation; 2011 Jan; 18(1):24-35. PubMed ID: 21166923
[TBL] [Abstract][Full Text] [Related]
32. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG
Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of myosin light chain phosphorylation decreases rat mesenteric lymphatic contractile activity.
Wang W; Nepiyushchikh Z; Zawieja DC; Chakraborty S; Zawieja SD; Gashev AA; Davis MJ; Muthuchamy M
Am J Physiol Heart Circ Physiol; 2009 Aug; 297(2):H726-34. PubMed ID: 19525378
[TBL] [Abstract][Full Text] [Related]
34. Substance P enhances NF-kappaB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways.
Sun J; Ramnath RD; Zhi L; Tamizhselvi R; Bhatia M
Am J Physiol Cell Physiol; 2008 Jun; 294(6):C1586-96. PubMed ID: 18434625
[TBL] [Abstract][Full Text] [Related]
35. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R).
Chernova I; Lai JP; Li H; Schwartz L; Tuluc F; Korchak HM; Douglas SD; Kilpatrick LE
J Leukoc Biol; 2009 Jan; 85(1):154-64. PubMed ID: 18835883
[TBL] [Abstract][Full Text] [Related]
36. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
